IP Library Granted Patent US 7,470,510
Granted Patent B2
US 7,470,510 · App. 10/364,515 · Granted Dec 30, 2008

Methods for diagnosing cancer and determining a susceptibility for developing cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,470,510
App. No.
10/364,515
Granted
Dec 30, 2008
Kind
B2
Abstract

A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence endcoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, area also disclosed.

Claims (31)

1. A method for determining whether a human subject harbors a mutation in an hMYH gene of the human subject that decreases an activity of the encoded hMYH protein, said method comprising:

providing an hMYH-encoding nucleotide sequence of the human subject; and

determining the presence or absence of a difference in a coding region in said hMYH-encoding nucleotide sequence, relative to SEQ ID NO:1, which results in decreased binding of the encoded hMYH protein to a substrate containing an A/GO mispair, or decreased glycosylase activity of the encoded hMYH protein on the mispaired adenosine in an A/GO mispair in a substrate containing an A/GO mispair.

2. The method of claim 1 , wherein said mutation is a substitution, a deletion, or an insertion.

3. The method of claim 1 , wherein said mutation results in a frame shift in, or a truncation of, the coding region.

4. The method of claim 1 , wherein said hMYH-encoding nucleotide sequence is a complementary DNA sequence.

5. The method of claim 4 , wherein the step of providing the hMYH-encoding nucleotide sequence comprises:

obtaining a sample from said patient;

isolating an hMYH-encoding nucleic acid from said sample; and

determining the nucleotide sequence of said hMYH-encoding nucleic acid.

6. The method of claim 5 , wherein said step of determining the nucleotide sequence of said hMYH-encoding nucleic acid is by DNA sequencing.

7. The method of claim 5 , further comprising amplifying a portion of said hMYH-encoding nucleic acid and determining the nucleotide sequence of the amplified nucleic acid.

8. The method of claim 5 wherein said sample is a blood sample, a urine sample, a saliva sample, a tissue biopsy sample, or an autopsy material sample.

9. The method of claim 8 wherein said sample is a blood sample.

10. A method for determining whether a human subject harbors a mutation in an hMYH gene of the human subject that decreases an activity of the encoded hMYH protein, said method comprising:

isolating an hMYH-encoding nucleic acid from a sample obtained from the human subject; and

determining the presence or absence of a mutation in a coding region in said hMYH-encoding nucleic acid, relative to SEQ ID NO:1, which results in decreased binding of the encoded hMYH protein to a substrate containing an A/GO mispair, or decreased glycosylase activity of the encoded hMYH protein on the mispaired adenosine in an A/GO mispair in a substrate containing an A/GO mispair.

11. The method of claim 10 wherein said mutation is a substitution, a deletion, or an insertion.

12. The method of claim 10 wherein said mutation results in a frame shift in, or a truncation of, the coding region.

13. The method of claim 10 wherein said hMYH-encoding nucleic acid is a complementary DNA.

14. The method of claim 10 wherein said hMYH-encoding nucleic acid is a genomic DNA.

15. The method of claim 10 wherein the step of determining the presence or absence of a mutation comprises amplifying said coding region in said hMYH-encoding nucleic acid.

16. The method of claim 15 wherein the step of determining the presence or absence of a mutation comprises detecting a change in the length of the amplified coding region.

17. The method of claim 15 wherein the step of determining the presence or absence of a mutation comprises nucleic acid hybridization.

18. The method of claim 10 further comprising

deducing the amino acid sequence encoded by the isolated hMYH-encoding nucleic acid; and

identifying a difference in the deduced amino acid sequence, relative to SEQ ID NO:2.

19. A method for determining whether a human subject harbors a mutation in an hMYH gene of the human subject that decreases an activity of the encoded hMYH protein, said method comprising:

Providing an amino acid sequence of an hMYH polypeptide of the human subject; and

determining the presence or absence of a difference in said amino acid sequence, relative to SEQ ID NO:2, which results in decreased binding of the encoded hMYH protein to a substrate containing an A/GO mispair or decreased glycosylase activity of the encoded hMYH protein on the mispaired adenosine in an A/GO mispair in a substrate containing an A/GO mispair.

20. The method of claim 19 , wherein said difference in said hMYH polypeptide sequence is a substitution, insertion, deletion or truncation.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2023
From: JPMORGAN CHASE BANK, N.A.
To: MYRIAD GENETICS, INC.; CRESCENDO BIOSCENCE, INC.; MYRIAD RBM, INC.; MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 064239/0091 →
SECURITY INTEREST Recorded Dec 27, 2016
From: MYRIAD GENETICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 041198/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2013
From: HUMAN GENOME SCIENCES, INC.
To: MYRIAD GENETICS, INC.
Reel/Frame 030841/0317 →